Drug Approval | April 14, 2026
FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The company says the platform offers improved manufacturability and functional advantages
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
He brings extensive cross-functional expertise built through leadership roles
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated
